Publication | Closed Access

Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus

VaccinationCross-protectionImmunologyAdjuvant UseTherapeutic VaccineInfluenza VaccineFlu VaccinationPolyvalent VaccineImmunotherapyMedicineProtective ImmunityVaccine DesignInfluenza A VirusInfluenza Vaccines